Top

CardioVascular and Interventional Radiology

27-09-2024 | Cytostatic Therapy | Study Protocol

Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol

Authors: N. Kalra, H. Bhujade, A. Baloji, D. Khosla, S. Samra, R. Srinivasan, P. Gupta, H. Singh, V. Gupta, R. Kapoor, D. Dahiya, R. Gupta, K. Kishore, M. Sandhu

Published in: CardioVascular and Interventional Radiology

Abstract

Purpose

This study aims to evaluate the feasibility and efficacy of chemotherapy combined with irreversible electroporation (IRE) in patients with locally advanced gallbladder carcinoma (GBC) presenting as gallbladder masses.

Materials and Methods

Patients with unresectable GBC masses of size greater than 2 cm and less than 6 cm without evidence of distant metastases and with no contraindication to general anaesthesia will be enrolled in the study. They will be randomized using computer generated table into two arms with 1:1 allocation ratio to include 15 patients in each group. Group I will be the chemotherapy alone arm and Group II will be the combined image-guided irreversible electroporation of the tumour and chemotherapy arm. The primary outcome assessed shall be the clinical benefit rate (complete response, CR; partial response, PR and stable disease, SD) based on the mRECIST criteria and overall survival. The secondary outcome shall be feasibility and safety of the procedure and quality of life pre and post procedure. The quality of life will be assessed by a questionnaire as given by EORTC-Quality of Life Group before starting therapy and 4 weeks after completion of therapy.

Expected Gain of Knowledge

The combined local and systemic effects of irreversible electroporation and systemic chemotherapy respectively may improve the outcomes in inoperable cases of gallbladder carcinoma.

Trial Registration

Clinical Trials Registry – India (https://ctri.nic.in/Clinicaltrials/advancesearchmain.php). Identifier: CTRI/2021/05/033803. Primary Register of the International Clinical Trials Registry Platform (WHO ICTRP) (http://www.who.int/ictrp/search/en/).

Graphic Abstract

Available only for authorised users

Ouyang G, Liu Q, Wu Y, Liu Z, Lu W, Li S, et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the global burden of disease study 2017. Cancer. 2021;127:2238–50. https://doi.org/10.1002/cncr.33476.CrossRefPubMed

Yang XW, Yang J, Li L, Man XB, Zhang BH, Shen F, et al. Analysis of the relationships between clinicopathologic factors and survival in gallbladder cancer following surgical resection with curative intent. PLoS ONE. 2012;7:e51513. https://doi.org/10.1371/journal.pone.0051513.CrossRefPubMedPubMedCentral

Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23:3978–98. https://doi.org/10.3748/wjg.v23.i22.3978.CrossRefPubMedPubMedCentral

Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357.CrossRefPubMedPubMedCentral

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. https://doi.org/10.1056/NEJMoa0908721.CrossRefPubMed

Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, et al. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2011;67:519–25. https://doi.org/10.1007/s00280-010-1351-8.CrossRefPubMed

Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer. 2004;90:1516–20. https://doi.org/10.1038/sj.bjc.6601736.CrossRefPubMedPubMedCentral

Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31. https://doi.org/10.1007/s10439-005-8981-8.CrossRefPubMed

Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25:997–1011. https://doi.org/10.1016/j.jvir.2014.01.028.CrossRefPubMed

10.

Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans Biomed Eng. 2015;62:4–20. https://doi.org/10.1109/TBME.2014.2367543.CrossRefPubMed

11.

Narayanan G, Froud T, Suthar R, Barbery K. Irreversible electroporation of hepatic malignancy. Semin Intervent Radiol. 2013;30:67–73. https://doi.org/10.1055/s-0033-1333655.CrossRefPubMedPubMedCentral

12.

Wagstaff PG, Buijs M, van den Bos W, de Bruin DM, Zondervan PJ, de la Rosette JJ, et al. Irreversible electroporation: state-of-the-art. Onco Targets Ther. 2016;9:2437–46. https://doi.org/10.2147/OTT.S88086.CrossRefPubMedPubMedCentral

13.

Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther. 2010;10:729–46. https://doi.org/10.1586/era.10.43.CrossRefPubMed

14.

Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS ONE. 2013;8(3):e59557. https://doi.org/10.1371/journal.pone.0059557.CrossRefPubMedPubMedCentral

15.

Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J. Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol. 2014;37:1523–9. https://doi.org/10.1007/s00270-014-0988-9.CrossRefPubMed

16.

Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:43687. https://doi.org/10.1038/srep43687.CrossRefPubMedPubMedCentral

17.

Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience. Cardiovasc Intervent Radiol. 2019;42:584–90. https://doi.org/10.1007/s00270-019-02164-2.CrossRefPubMed

18.

Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275–81. https://doi.org/10.21037/jgo.2018.01.14.CrossRefPubMedPubMedCentral

19.

Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486–94. https://doi.org/10.1097/SLA.0000000000001441.CrossRefPubMed

20.

Canvasser NE, Sorokin I, Lay AH, Morgan MSC, Ozayar A, Trimmer C, et al. Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series. World J Urol. 2017;35:1549–55. https://doi.org/10.1007/s00345-017-2025-5.CrossRefPubMed

21.

Trimmer CK, Khosla A, Morgan M, Stephenson SL, Ozayar A, Cadeddu JA. Minimally invasive percutaneous treatment of small renal tumors with irreversible electroporation: a single-center experience. J Vasc Interv Radiol. 2015;26:1465–71. https://doi.org/10.1016/j.jvir.2015.06.028.CrossRefPubMed

22.

van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2018;121:716–24. https://doi.org/10.1111/bju.13983.CrossRefPubMed

23.

Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS ONE. 2019;14:e0215093. https://doi.org/10.1371/journal.pone.0215093.CrossRefPubMedPubMedCentral

24.

Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, et al. High-voltage pulses in oncology: Irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology. 2020;295:254–72. https://doi.org/10.1148/radiol.2020192190.CrossRefPubMed

25.

Calvet CY, Mir LM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev. 2016;35:165–77. https://doi.org/10.1007/s10555-016-9615-3.CrossRefPubMedPubMedCentral

26.

Campana LG, Miklavčič D, Bertino G, Marconato R, Valpione S, Imarisio I, et al. Electrochemotherapy of superficial tumors—current status: basic principles, operating procedures, shared indications, and emerging applications. Semin Oncol. 2019;46:173–91. https://doi.org/10.1053/j.seminoncol.2019.04.002.CrossRefPubMed

27.

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and Elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRefPubMedPubMedCentral

28.

Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer—a systematic review. Eur J Surg Oncol. 2019;45:83–91. https://doi.org/10.1016/j.ejso.2018.08.020.CrossRefPubMed

29.

Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6. https://doi.org/10.1007/s00270-017-1703-4.CrossRefPubMed

30.

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:28–37. https://doi.org/10.1093/annonc/mdw324.CrossRef

31.

Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541–65. https://doi.org/10.6004/jnccn.2021.0022.CrossRefPubMed

32.

Yang PC, Chen YJ, Li XY, Hsiao CY, Cheng BB, Gao Y, et al. Irreversible electroporation treatment with intraoperative biliary stenting for unresectable perihilar cholangiocarcinoma: a pilot study. Front Oncol. 2021;11:710536. https://doi.org/10.3389/fonc.2021.710536.CrossRefPubMedPubMedCentral

33.

Hsiao CY, Yang PC, Li X, Huang KW. Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma. Sci Rep. 2020;10:10883. https://doi.org/10.1038/s41598-020-67772-2.CrossRefPubMedPubMedCentral

34.

Ma Y, Chen Z, Zhu W, Yu J, Ji H, Tang X, et al. Chemotherapy plus concurrent irreversible electroporation improved local tumor control in unresectable hilar cholangiocarcinoma compared with chemotherapy alone. Int J Hyperthermia. 2021;38:1512–8. https://doi.org/10.1080/02656736.2021.1991008.CrossRefPubMed

35.

Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9(2):275–81. https://doi.org/10.21037/jgo.2018.01.14.CrossRefPubMedPubMedCentral

36.

He C, Wang J, Sun S, Zhang Y, Lin X, Lao X, et al. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. BMC Cancer. 2019;19(1):394. https://doi.org/10.1186/s12885-019-5607-3.CrossRefPubMedPubMedCentral

37.

Ma Y, Xing Y, Li H, Liang B, Li R, Li J, et al. Simultaneous gemcitabine and percutaneous CT-guided irreversible electroporation for locally advanced pancreatic cancer. J Oncol. 2022;2022:3523769. https://doi.org/10.1155/2022/3523769.CrossRefPubMedPubMedCentral

38.

Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, et al. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341–50. https://doi.org/10.2147/OTT.S186721.CrossRefPubMedPubMedCentral

39.

Ma Y, Xing Y, Li H, Yuan T, Liang B, Li R, et al. Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer. Front Immunol. 2023;14:1193040. https://doi.org/10.3389/fimmu.2023.1193040.CrossRefPubMedPubMedCentral

Title: Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol
Authors: N. Kalra
H. Bhujade
A. Baloji
D. Khosla
S. Samra
R. Srinivasan
P. Gupta
H. Singh
V. Gupta
R. Kapoor
D. Dahiya
R. Gupta
K. Kishore
M. Sandhu
Publication date: 27-09-2024
Publisher: Springer US
Keyword: Cytostatic Therapy
Published in: CardioVascular and Interventional Radiology
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-024-03856-0

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol

Abstract

Purpose

Materials and Methods

Expected Gain of Knowledge

Trial Registration

Graphic Abstract

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose

Materials and Methods

Expected Gain of Knowledge

Trial Registration

Graphic Abstract

Please log in to get access to this content